NEVVI Medicare utilization intelligence
or

← back

Provider profile

LIPMAN, ANDREW M.D.

Hematology-Oncology · NPI 1780654889 · NAPLES, FL

1
Groups
72
Codes · 2024
443,685
Disclosed services

LIPMAN, ANDREW is a Hematology-Oncology in NAPLES, FL, a member of 1 medical group, who billed 72 distinct codes to Medicare Part B in 2024.

Groups: FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC (FORT MYERS, FL)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

443,685
disclosed services
72
codes billed to Medicare Part B
Prior year · CY2023 436,219 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9025 Injection, azacitidine, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J0185 Injection, aprepitant, 1 mg
J9299 Injection, nivolumab, 1 mg
J1442 Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram
J9263 Injection, oxaliplatin, 0.5 mg
J9264 Injection, paclitaxel protein-bound particles, 1 mg
J0897 Injection, denosumab, 1 mg
J1434 Injection, fosaprepitant (focinvez), 1 mg
J9267 Injection, paclitaxel, 1 mg
Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1437 Injection, ferric derisomaltose, 10 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
J9041 Injection, bortezomib, 0.1 mg
J9171 Injection, docetaxel, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J0461 Injection, atropine sulfate, 0.01 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2405 Injection, ondansetron hydrochloride, per 1 mg
Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J2919 Injection, methylprednisolone sodium succinate, 5 mg
J0640 Injection, leucovorin calcium, per 50 mg
96372 Injection of drug or substance under skin or into muscle
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J9190 Injection, fluorouracil, 500 mg
Q5127 Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
J9395 Injection, fulvestrant, 25 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
J7030 Infusion, normal saline solution , 1000 cc
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96415 Administration of chemotherapy into vein, each additional hour
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J9045 Injection, carboplatin, 50 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
96360 Infusion into a vein for hydration, 31-60 minutes
96361 Infusion into a vein for hydration, each additional hour
J3489 Injection, zoledronic acid, 1 mg
96411 Administration of additional new drug or substance into vein using push technique
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3475 Injection, magnesium sulfate, per 500 mg
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96374 Injection of drug or substance into vein
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99195 Drawing of blood for a medical problem
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99497 Advance care planning, first 30 minutes
81003 Automated urinalysis test
85045 Red blood count, automated test
85046 Red blood count automated, with additional calculations
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
99496 Transitional care management services for problem of high complexity
99495 Transitional care management services for problem of at least moderate complexity

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.